Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001534074 | SCV001750969 | uncertain significance | not provided | 2021-04-30 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Although located in a calcium-binding EGF-like domain of the FBN1 gene, it does not affect a cysteine residue within this domain; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003) |
Ambry Genetics | RCV003161071 | SCV003863078 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2022-11-15 | criteria provided, single submitter | clinical testing | The p.N2456H variant (also known as c.7366A>C), located in coding exon 59 of the FBN1 gene, results from an A to C substitution at nucleotide position 7366. The asparagine at codon 2456 is replaced by histidine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004008919 | SCV004837619 | uncertain significance | Marfan syndrome | 2023-11-30 | criteria provided, single submitter | clinical testing |